NAS10029,813+0.55%S&P7,744+0.28%GOLD$4,077+0.07%BTC$81,598+0.98%VIX16.87−3.71%latest tape · as of 20:04 UTC · 28 Oct
The Screen · Healthcare · Biotechnology
Kodiak Sciences Inc.
KOD · Nasdaq · USD · Market cap $5.5B · 130 employees
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
FAIL · Does not pass the screen
87.63 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 20:04 UTC · 28 Oct · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price87.63 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans to puts (put/call 1.22)
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 87.63 against the desk's fair-value range, base estimate 122.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.22, read 2026-10-23
Ethical does not pass the values gate
Price87.63 USD
Fair value122.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markup32.42+170.3% to today ✓Markdown gives way to Markup after an 18% slide in 4 weeks
2026-09-03Read Markdown39.33+122.8% to today Markup gives way to Markdown after an 8% slide in 4 weeks
2026-08-04Read Markup42.64+105.5% to today ✓Markdown gives way to Markup after a 25% rise in 5 weeks
2026-07-02Read Markdown34.06+157.3% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Kodiak Sciences Inc. holds its Markup at $87.63. Elevated stress, defensive posture warranted, held for 17 days.
As held on the ledger · 2026-10-23
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 17 days
Price at the screen
$87.63
Valuation
N/A trailing · -25.53 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.04
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
16.83%
Below 33%
Interest-bearing debt is just 16.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
59.70%
Below 49%
Money owed to the company is 59.7% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Kodiak Sciences's business is fine, but its receivables are about 60% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when KOD's ethical verdict changes
Today KOD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 39.1% margin of safety to the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +39% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech eye drug bet lacks financial proof
Imagine a lab racing to treat failing eyesight with one unproven injection while the books show zero profit and deep losses. Kodiak Sciences sits in exactly that spot, a clinical stage developer of retinal therapies whose lead candidate still needs years of trials. We pass because the ethical screen returns insufficient data and the opportunity rating sits at none.
The numbers tell a clear story of early stage risk. Forward earnings sit at a negative 13.7 times, profit margins remain at zero and return on equity runs at minus 209 percent. Analyst targets hover around 60 dollars yet carry no consensus rating, leaving investors to guess at timing and success.
Currency and trial failure sit at the centre of the downside. A single missed endpoint or delayed approval could wipe out the apparent margin of safety without any operating cash flow to cushion the fall. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KOD trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup$87.72-4.3%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 127% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63. Insiders have been net buyers over the past quarter. Since the last review it its composite score rose.
2026-10-21Markup$91.63-8.3%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 8.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 133% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63. Insiders have been net buyers over the past quarter.
2026-10-14Markup$99.87+208.1%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 208.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63. Insiders have been net buyers over the past quarter.
2026-10-02Markup · changed$32.42-17.6%Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 17.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63. Insiders have been net buyers over the past quarter.
2026-09-03Markdown · changed$39.33-7.8%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63.
2026-08-04Markup · changed$42.64+25.2%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 25.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63.
2026-07-18Markdown$34.06+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 47% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 648%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (6 analysts) rates it none, with a mean price target of $63.
2026-07-03Markdown$34.06+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$34.06Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
